This article is more than 5 years old. Information may no longer be current.
Patient information program may increase antipsychotic adherence
Click Here to Manage Email Alerts
SAN ANTONIO — Approximately 80% of individuals involved in a patient information program were adherent to long-acting injectable paliperidone palmitate or risperidone medication, according to data presented at U.S. Psychiatric and Mental Health Congress.
To assess 1-year medication adherence among individuals enrolled in Janssen Connect, a patient information program developed to provide information and assistance to individuals prescribed long-acting injectable paliperidone palmitate or risperidone, researchers conducted a retrospective cohort study of more than 30,000 patients enrolled in the program. Study participants received at least two injections of long-acting paliperidone palmitate through the program, received their first injection at least 1 year before the end of data availability and did not switch from paliperidone palmitate to risperidone during enrollment (n = 1,693). Approximately half the cohort was aged 35 years and older. The median number of injections was nine.
Overall, 78% to 88% of participants with commercial, Medicare, Medicaid or no coverage were adherent.
Researchers observed the largest gap among participants with other government coverage, excluding Medicaid and Medicare, where 64% were adherent.
“Over more than 4 years of program experience, 80.7% of patients who received their injections from the program were observed to be adherent,” the researchers wrote. “Comparable adherence rates were observed across different subgroups, including those groups that typically have challenges in adhering to their medications.” – by Amanda Oldt
Reference:
Park SH, et al. Adherence to atypical antipsychotic long-acting injectables among patients with schizophrenia enrolled in a patient information program. Presented at: U.S. Psychiatric and Mental Health Congress; Oct. 21-24, 2016; San Antonio.
Disclosure: The study was funded by Janssen Scientific Affairs, LLC.